Salud financiera de hoja de balance de CureVac
Salud financiera controles de criterios 5/6
CureVac tiene unos fondos propios totales de €602.3M y una deuda total de €0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son €842.6M y €240.3M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
€0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | €464.15m |
| Patrimonio | €602.27m |
| Total pasivo | €240.30m |
| Activos totales | €842.57m |
Actualizaciones recientes sobre salud financiera
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20
Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Recent updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma
Feb 04Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates
Jan 11CureVac, Bayer agree to COVID-19 vaccine alliance - report
Jan 07Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Curevac advances COVID-19 vaccine candidate to Phase 3 trial
Dec 21CureVac commences global mid-stage trial for COVID-19 vaccine candidate
Dec 14CureVac rises 7% on manufacturing deal for COVID-19 vaccine candidate
Dec 09Análisis de la situación financiera
Pasivos a corto plazo: CVACLos activos a corto plazo (€536.8M) de la empresa superan a sus pasivos a corto plazo (€150.7M).
Pasivo a largo plazo: CVACLos activos a corto plazo (€536.8M) superan a sus pasivos a largo plazo (€89.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CVAC está libre de deudas.
Reducción de la deuda: CVAC no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CVAC tiene suficiente margen de tesorería para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si CVAC tiene suficiente margen de liquidez en caso de que su flujo de caja libre siga creciendo o disminuyendo en función de las tasas históricas.